Defining the clinical course of multiple sclerosis
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Abstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Neurology
- Topic
- Multiple Sclerosis Research Studies
- Field
- Medicine
- Canadian institutions
- —
- Funders
- National Institute of Neurological Disorders and StrokeEMD SeronoAcorda TherapeuticsUniversity of CambridgeBayer CanadaNational Institutes of HealthMultiple Sclerosis SocietySchweizerische Multiple Sklerose GesellschaftEisaiNational Institute for Health and Care ResearchNational Research FoundationWolfson FoundationGenentechEuropean CommissionGlenmark PharmaceuticalsMultiple Sclerosis International FederationSanofiGW PharmaceuticalsAlexion PharmaceuticalsMyelin Repair FoundationBayer HealthCareGrifolsF. Hoffmann-La RocheIronwood Pharmaceuticals, IncorporatedEli Lilly and CompanyUniversity of AlabamaWellcome TrustEuropean Committee for Treatment and Research in Multiple SclerosisSanofi GenzymeUniversity of Alabama at BirminghamMedical Research CouncilTeva Pharmaceutical IndustriesGilead SciencesGlaxoSmithKlineUniversity of Texas Health Science Center at HoustonCelgeneNatural Sciences and Engineering Research Council of CanadaPfizerBiogenSerono Symposia International FoundationNovartis Pharmaceuticals CorporationNational Multiple Sclerosis SocietyNational Heart, Lung, and Blood InstituteSun PharmaCleveland ClinicCanadian Institutes of Health ResearchProthenaAmylin Pharmaceuticals
- Keywords
- Multiple sclerosisClinical trialClinical phenotypeDiseaseMedicineClinical diseasePhenotypeMedical physicsPathologyIntensive care medicineBioinformaticsBiologyPsychiatry
- Has abstract in OpenAlex
- yes